GlassScriptPhysician profile
Akhil Gupta
NPI 1083131395
$8,676.76
in general payments reported to CMS, 2019-2025
34 companies · $819 in 2025
The $819 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,331 · 2020: $1,234 · 2021: $1,078 · 2022: $1,578 · 2023: $1,359 · 2024: $1,278 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,275 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,275.43 |
| Education | $179.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,284.21 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,112.18 | 2019-2025 | Dupixent |
| Incyte Corporation | $486.92 | 2021-2025 | Opzelura |
| Genzyme Corporation | $455.85 | 2020-2025 | |
| Lilly USA, LLC | $423.27 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $393.87 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $369.39 | 2021-2025 | Ilumya |
| Janssen Biotech, INC. | $363.80 | 2020-2023 | Tremfya, Stelara, Remicade |
| Novartis Pharmaceuticals Corporation | $315.19 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $280.80 | 2022-2024 | Sotyktu |
| Allergan, INC. | $274.63 | 2019-2022 | |
| Galderma Laboratories, L.P. | $254.48 | 2019-2025 | Nemluvio |
| Genentech USA, INC. | $246.32 | 2019-2024 | Activase |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $210.60 | 2021-2023 | Arazlo, Jublia |
| Vyne Pharmaceuticals INC. | $176.83 | 2020-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $166.63 | 2020-2022 | |
| Dermavant Sciences, INC. | $158.50 | 2024 | Vtama |
| Sanofi-Aventis U.S. LLC | $149.95 | 2021-2024 | |
| Arcutis Biotherapeutics, INC. | $107.62 | 2023-2025 | Zoryve |
| Celgene Corporation | $78.37 | 2019 | |
| Pfizer INC. | $55.28 | 2019-2023 | |
| Novo Nordisk INC | $49.30 | 2024 | |
| Leo Pharma INC. | $34.79 | 2024 | Adbry |
| Helsinn Therapeutics (U.S.), INC. | $34.54 | 2021 | |
| Smith+Nephew, INC. | $28.60 | 2021 | |
| Almirall LLC | $27.66 | 2023 | Klisyri |
| Ucb, INC. | $23.98 | 2022 | |
| Mayne Pharma Commercial LLC | $23.29 | 2022 | |
| Journey Medical Corporation | $23.17 | 2025 | |
| Lnhc, INC | $21.31 | 2025 | Zelsuvmi |
| Mimedx Group, INC. | $13.40 | 2024 | |
| Strata Skin Sciences, INC. | $13.01 | 2022 | |
| Biofrontera INC. | $12.16 | 2021 | |
| Organon LLC | $6.86 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akhil Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.